IceCure Ltd. (TASE: ICCM) has announced that, as part of a clinical trial at Kameda Medical Center in Japan, two lung cancer patients in Japan were successfully treated with the company’s IceSense3 cryotherapy system. Kameda Medical Center is fully funding the study.
IceCure’s system already destroys benign tumors, in addition to a clinical trial in the US for the treatment of breast cancer tumors, and now the clinical trial in Japan. Lung cancer is the most frequent cause of death among cancer patients, and IceCure’s successful entry into this market greatly increases its business potential.
IceCure president and CEO Hezi Himelfarb said, “We’re pleased at the success in destroying lung cancer tumors because use of our cryoablation platform could open to us a potential market of hundreds of thousands of new cases in the US alone. Treatment with IceCure’s system, which is a minimally invasive procedure, has clear advantages over complicated and expensive surgical solutions for excising tumors, which involve hospital stays, surgery, and prolonged recovery. We believe that further success in the breast cancer clinical trial in the US and the lung cancer clinical trial in Japan positions IceCure in a good place and paves the way to participating in these opportunities.”
After the trial is completed and the results are analyzed, IceCure will examine the extent of its involvement in the treatment of lung cancer by cryoablation. A preclinical trial on animals at Kameda Medical Center found it more effective compared with other cryoablation methods.
Studies in the US have found that lung cancer is the biggest killer of all types of cancer in both men and women, accounting for more deaths than the next three cancers (colon cancer, breast cancer, and prostate cancer) combined.
Published by www.globes-online.com